Genmab has raised gross proceeds of DKK 998 million ($183 million) following pricing of its previously announced private placement financing.

Genmab will issue 4,600,000 new shares with a nominal value of DKK 1 each at a price of DKK 217 per share.

Potential uses for the net proceeds from the transaction may include, among other things, and without limiting Genmab's discretion, the funding of:

Clinical development of HuMax-TF-ADC (currently in a Phase I study in eight solid tumors) and Progressing Genmab’s pipeline of pre-clinical projects towards clinical development.

View the full article at Genmab website.

For further financing deal information visit Current Agreements (subscription required)

Related

Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter